Clinical trial
Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With…
NCT00120796 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Terminated
Key facts
| NCT number | NCT00120796 |
|---|---|
| Title | Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2) |
| Official title | Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological, Drug |
| Interventions | Lamivudine, Recombinant hepatitis B surface antigen |
| Enrollment | 8 |
| Start date | Aug 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jul 19, 2005 |
| Last update posted | Jul 21, 2016 |
| Countries | Senegal |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: